Helmut Thomas
Directeur Général chez Cyclenium Pharma, Inc.
Profil
Helmut Thomas is the President, CEO & Chief Scientific Officer at Cyclenium Pharma, Inc. He previously worked as an Executive Director at Novartis Pharma NV and as a Principal at Ciba-Geigy Corp.
He also served as the Senior VP-Research & Preclinical Development at Ocera Therapeutics, Inc. from 2011 to 2013 and as the Vice President-Drug Development at LymphoSign, Inc. from 2004 to 2009.
Dr. Thomas earned a doctorate degree from the University of Hannover in 1984.
Postes actifs de Helmut Thomas
| Sociétés | Poste | Début |
|---|---|---|
Cyclenium Pharma, Inc.
 Cyclenium Pharma, Inc. Pharmaceuticals: MajorHealth Technology Cyclenium Pharma, Inc. is a privately held pharmaceutical research and development company based in Montréal, Canada. The Canadian company is focused on creating value through the progression of internal programs in oncology, infectious diseases, and inflammation/pain. Cyclenium is also providing its extensive experience and exploring its CMRT-based Quest™ screening library in risk-sharing partnerships with leading academic and research-driven non-profit organizations, as well as collaborations with innovative pharmaceutical and biotechnology companies worldwide seeking to modulate unique and difficult disease targets in diverse therapeutic areas. The company was founded by Mark L. Peterson, and the CEO is Helmut Thomas. | Directeur Général | - |
Anciens postes connus de Helmut Thomas
| Sociétés | Poste | Fin |
|---|---|---|
| OCERA THERAPEUTICS INC | Directeur Technique/Scientifique/R&D | - |
Novartis Pharma NV
 Novartis Pharma NV Pharmaceuticals: MajorHealth Technology Founded in 1996, Novartis Pharma NV is a Belgian pharmaceutical company that develops medicines. The company is based in Brussels, Belgium and is a subsidiary of Novartis AG. | Directeur/Membre du Conseil | - |
| Ciba-Geigy Corp. | Corporate Officer/Principal | - |
LymphoSign, Inc.
 LymphoSign, Inc. BiotechnologyHealth Technology LymphoSign, Inc. develops drugs for the cancer treatment. It also develops drugs acting on signaling pathways involved in the progression of acute leukemias, lymphomas and solid tumors. The company was founded by Chaim Roifman in 2000 and is headquartered in Markham, Canada. | Directeur Technique/Scientifique/R&D | - |
Formation de Helmut Thomas
| University of Hannover | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
| Ciba-Geigy Corp. | Health Technology |
Ocera Therapeutics, Inc.
 Ocera Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ocera Therapeutics, Inc. manufactures pharmaceuticals products. The company was founded in 2004 and is headquartered in Hazelwood, MO. | Health Technology |
LymphoSign, Inc.
LymphoSign, Inc. BiotechnologyHealth Technology LymphoSign, Inc. develops drugs for the cancer treatment. It also develops drugs acting on signaling pathways involved in the progression of acute leukemias, lymphomas and solid tumors. The company was founded by Chaim Roifman in 2000 and is headquartered in Markham, Canada. | Health Technology |
Novartis Pharma NV
Novartis Pharma NV Pharmaceuticals: MajorHealth Technology Founded in 1996, Novartis Pharma NV is a Belgian pharmaceutical company that develops medicines. The company is based in Brussels, Belgium and is a subsidiary of Novartis AG. | Health Technology |
Cyclenium Pharma, Inc.
Cyclenium Pharma, Inc. Pharmaceuticals: MajorHealth Technology Cyclenium Pharma, Inc. is a privately held pharmaceutical research and development company based in Montréal, Canada. The Canadian company is focused on creating value through the progression of internal programs in oncology, infectious diseases, and inflammation/pain. Cyclenium is also providing its extensive experience and exploring its CMRT-based Quest™ screening library in risk-sharing partnerships with leading academic and research-driven non-profit organizations, as well as collaborations with innovative pharmaceutical and biotechnology companies worldwide seeking to modulate unique and difficult disease targets in diverse therapeutic areas. The company was founded by Mark L. Peterson, and the CEO is Helmut Thomas. | Health Technology |
